Total Payments
$770,154
2024 Payments
$150,238
Companies
20
Transactions
888
Medicare Patients
1,684
Medicare Billing
$214,803
Payment Breakdown by Category
Other$556,572 (72.3%)
Consulting$142,438 (18.5%)
Travel$48,546 (6.3%)
Food & Beverage$21,480 (2.8%)
Education$1,040 (0.1%)
Gifts$78.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $470,965 | 177 | 61.2% |
| Consulting Fee | $142,438 | 47 | 18.5% |
| Honoraria | $85,607 | 30 | 11.1% |
| Travel and Lodging | $48,546 | 245 | 6.3% |
| Food and Beverage | $21,480 | 374 | 2.8% |
| Education | $1,040 | 14 | 0.1% |
| Gift | $78.75 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $269,461 | 283 | $0 (2024) |
| Biogen, Inc. | $178,032 | 172 | $0 (2024) |
| Horizon Therapeutics plc | $99,843 | 108 | $0 (2023) |
| Genentech USA, Inc. | $76,472 | 66 | $0 (2024) |
| Amgen Inc. | $61,744 | 74 | $0 (2024) |
| GENZYME CORPORATION | $35,398 | 52 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $16,160 | 26 | $0 (2018) |
| Celgene Corporation | $11,747 | 31 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $10,218 | 9 | $0 (2022) |
| UCB, Inc. | $5,569 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $150,238 | 192 | Alexion Pharmaceuticals, Inc. ($81,309) |
| 2023 | $179,187 | 193 | Alexion Pharmaceuticals, Inc. ($89,018) |
| 2022 | $86,963 | 104 | Alexion Pharmaceuticals, Inc. ($27,747) |
| 2021 | $54,765 | 50 | Biogen, Inc. ($16,733) |
| 2020 | $81,383 | 73 | Biogen, Inc. ($48,568) |
| 2019 | $88,628 | 125 | Alexion Pharmaceuticals, Inc. ($37,889) |
| 2018 | $57,067 | 71 | Biogen, Inc. ($28,892) |
| 2017 | $71,924 | 80 | Genentech USA, Inc. ($19,841) |
All Payment Transactions
888 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $2,949.38 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/24/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $2,212.03 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/22/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $5.71 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $4.47 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $7.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $5.63 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $61.18 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $11.36 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $9.47 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/10/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,020.00 | General |
| 12/02/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/26/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $72.87 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Genentech, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $118.45 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $5.94 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/12/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: Neurology | ||||||
| 11/05/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/04/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $21.91 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/04/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $13.95 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/02/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $344.95 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/02/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/02/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $123.73 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/02/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $89.36 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/02/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 406 | 501 | $148,644 | $52,876 |
| 2022 | 8 | 391 | 490 | $126,977 | $50,310 |
| 2021 | 8 | 450 | 538 | $150,203 | $60,302 |
| 2020 | 10 | 437 | 514 | $152,346 | $51,315 |
Total Patients
1,684
Total Services
2,043
Medicare Billing
$214,803
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 110 | 135 | $52,995 | $20,337 | 38.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 123 | 145 | $42,445 | $15,255 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 59 | 59 | $23,923 | $8,069 | 33.7% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 55 | 68 | $11,925 | $3,715 | 31.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 21 | $5,583 | $2,225 | 39.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 36 | $6,606 | $2,180 | 33.0% |
| 92133 | Imaging of optic nerve | Office | 2023 | 33 | 37 | $5,167 | $1,095 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 147 | 198 | $52,506 | $22,620 | 43.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 54 | 57 | $20,121 | $8,769 | 43.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $22,540 | $8,122 | 36.0% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 69 | 87 | $15,051 | $5,117 | 34.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 41 | $7,093 | $2,563 | 36.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $3,490 | $1,262 | 36.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 12 | $2,250 | $1,013 | 45.0% |
| 92133 | Imaging of optic nerve | Office | 2022 | 24 | 26 | $3,926 | $842.89 | 21.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 134 | 195 | $51,285 | $22,492 | 43.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 78 | 82 | $28,946 | $13,131 | 45.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 80 | 80 | $32,122 | $11,840 | 36.9% |
| 92083 | Measurement of field of vision during daylight conditions, extended examination | Office | 2021 | 85 | 103 | $17,819 | $6,145 | 34.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $5,533 | $2,010 | 36.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $5,346 | $2,003 | 37.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 21 | 24 | $4,320 | $1,644 | 38.1% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2021 | 30 | 32 | $4,832 | $1,037 | 21.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 154 | 189 | $66,717 | $23,138 | 34.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 74 | 86 | $22,618 | $7,328 | 32.4% |
About Benjamin Osborne
Benjamin Osborne is a Neurology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750310504.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Benjamin Osborne has received a total of $770,154 in payments from pharmaceutical and medical device companies, with $150,238 received in 2024. These payments were reported across 888 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($470,965).
As a Medicare-enrolled provider, Osborne has provided services to 1,684 Medicare beneficiaries, totaling 2,043 services with total Medicare billing of $214,803. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Washington, DC
- Active Since 07/02/2006
- Last Updated 03/14/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1750310504
Products in Payments
- UPLIZNA (Drug) $99,763
- SOLIRIS (Biological) $69,248
- TYSABRI (Biological) $66,051
- ULTOMIRIS (Biological) $61,423
- UPLIZNA (Biological) $61,188
- AUBAGIO (Drug) $34,951
- VUMERITY (Drug) $34,750
- TECFIDERA (Drug) $34,215
- OCREVUS (Biological) $33,136
- Soliris (Drug) $31,819
- Enspryng (Biological) $21,992
- Non-Covered Product (Drug) $21,356
- COPAXONE (Drug) $15,728
- ZEPOSIA (Drug) $11,775
- SOLIRIS (Drug) $11,670
- PLEGRIDY (Biological) $9,969
- Rystiggo (Drug) $2,609
- BRIUMVI (Drug) $2,582
- Zilbrysq (Biological) $840.00
- Ocrevus (Biological) $448.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Washington
Dr. Laxman Bahroo, D.o,, D.O,
Neurology — Payments: $3.4M
Neurology $3.4M
Dr. Fahd Amjad, Md, MD
Neurology — Payments: $2.4M
Neurology $2.4M
Jessica Ailani, Md, MD
Neurology — Payments: $1.3M
Neurology $1.3M
Fernando Pagan
Neurology — Payments: $1.1M
Neurology $1.1M
Dr. Yasar Torres-Yaghi, M.d, M.D
Neurology — Payments: $868,293
Neurology $868,293
Dr. Faria Amjad, Md, MD
Neurology — Payments: $671,517
Neurology $671,517